Evidence map›Paper›PMID 34918879›Full record

ArticleCancer medicine2022

Semen and serum platinum levels in cisplatin-treated survivors of germ cell cancer.

Eoghan R Malone, Jeremy Lewin, Xuan Li, Wen-Jiang Zhang, Susan Lau, Keith Jarvi, Robert J Hamilton, Aaron R Hansen, Eric X Chen, Philippe L Bedard

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Eoghan R MaloneDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0001-9012-7141
Jeremy LewinDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Xuan LiDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Wen-Jiang ZhangDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Susan LauMurray Koffler Urologic Wellness Centre, Mount Sinai Hospital, Joseph and Wolff Lebovic Health Complex, Toronto, Ontario, Canada.
Keith JarviDivision of Urology, University of Toronto, Toronto, Ontario, Canada.
Robert J HamiltonDivision of Urology, University of Toronto, Toronto, Ontario, Canada.
Aaron R HansenDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-2363-8707
Eric X ChenDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Philippe L BedardDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.ORCID 0000-0002-6771-2999
University Health Network · CAMount Sinai Hospital · CAUniversity of Toronto · CA

Funding

University of Toronto
6 · The paper itself

Abstract

backgroundTesticular cancer survivors often have impaired gonadal function possibly related to chemotherapy. Platinum is a heavy metal that can be detected at low levels in serum many years after treatment, it is not known whether platinum also persists in semen and if platinum persistence in semen is associated with impaired fertility.

methodsAdult cisplatin-treated testicular cancer survivors were enrolled. High-Performance Liquid Chromatography-tandem mass spectrometry was used to measure semen and serum platinum levels. Semen quality and DNA Fragmentation Index (DFI) were assessed.

resultsFrom 11/2017 to 12/2019, 38 patients (median age 32 years; range: 19-52) were enrolled. Median cumulative cisplatin dose was 301 mg/m

conclusionsPlatinum is detected in semen of testicular cancer survivors at higher levels than matched blood samples. These preliminary findings may have important implications for the reproductive health of survivors of advanced testicular cancer, further study is needed to assess the relationship between platinum persistence in semen and recovery of fertility postchemotherapy.

Indexed as

Neoplasms, Germ Cell and EmbryonalTesticular NeoplasmsAdultCisplatinHumansMalePlatinumSemenSemen AnalysisSurvivorsCisplatinPlatinumchemotherapy toxicitycisplatinfertilitysurvivorshiptesticular cancer

Identifiers

PMID34918879
PMCPMC8817086
OpenAlexW4200336107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.